Small Cap Feast

Small Cap Feast – 14 May 2019

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?

Main Market (Premium)

Jewel UK Midco Limited, the parent company of The Watches of Switzerland Group Limited, is looking to join the premium segment of the main market. Offer TBC, expect TBC

Finablr plc— global platform which provides Cross-Border Payments and Consumer Solutions, Consumer Foreign Exchange Solutions and B2B and Payment Technology Solutions to consumers and businesses in the large and growing payments and foreign exchange market is looking to list on the Main Market plans to raise $200m, expected May 2019

Main Market (Standard)

IMC Exploration Group (NEX: IMCP), focused on acquiring and exploring prospecting licence areas which have high potential for natural resource, is looking to admit its shares to the standard list and will withdraw for the NEX Exchange. Expected 11 June 2019


Essensys plc—a provider of mission-critical SaaS platforms and on-demand cloud services to the high growth flexible workspace industry, plans to join AIM. Offer TBC,  expected 29 May 2019.

Induction Healthcare Group plc—a healthcare technology company focused on streamlining the delivery of care by Healthcare Professionals looking to join AIM. Expected raise of £14.58m at 115p, market cap of £34.07m. Expected 22 May 2019.

SDX Energy plc—a North Africa focused oil and gas company, announces its intention to complete a Canadian plan of arrangement under section 192 of the Canada Business Corporations Act and will have shares de-listed from the TSX-V and admitted to trading on AIM. Expected 28 May 2019, anticipated market cap of £76m

Renold plc—a leading international supplier of industrial chains and related power transmission products, announced that it will cancel the listing of the Company from the premium segment and apply for admission on AIM. Expected 06 June 2019.

Alumasc Group plc, the premium building products, systems and solutions group, has announced its intention to move from the Premium Segment of the main market to AIM. Expected market cap of £33.4m. Expected 25 June 2019

NEX Exchange

Arbuthnot Banking Group plc, primarily involved in banking and financial services including commercial banking, private banking, wealth planning and investment management, is looking to joining the NEX Exchange Growth Market. Expected 17 May 2019

Breakfast Buffet

Concepta (CPT.L) 3.5p £9m

FY May 19 results from   the innovative UK personalised healthcare company and developer of the proprietary self-test platform (“myLotus®”)

Revenue of £0.00m (2017 : £0.10m)

EBITDA loss £2.65m (2017 : £2.3m loss)

Cash at year end £0.74m (2017 : £1.5m)

Completion of £2m (net of expenses) share placing at 4p per share in Aug 2018. A further £2.2m raised in April 2019 at 3p.

“Our priority for 2019 is to develop our UK sales channels in B2C and B2B and engage a sustainable growth model which we can extend across the EU.”

Separately  Concepta has announced  its first pregnancies and user testimonials for the myLotus® monitor and app.

Beeks Fin Cloud (BKS.L) 105p £53.2m

The “leading low-latency Infrastructure-as-a-Service (IaaS) provider for financial markets, announced that it is growing its portfolio of datacentre locations by deploying in the NY5 New York datacentre of global interconnection and data centre provider Equinix. In addition to this, Beeks has extended its current rackspace in Equinix’s LD4 datacentre in London by taking a third cage.

With presence in a total of eleven datacentres currently, this move allows Beeks to continue to increase its offering to customers, supplying the opportunity for further connectivity options to financial exchanges from the new location.”


Aortech (AOR.L) 70p £10.2m

“The licensor of the world’s leading long- term implantable biostable polymer (Elast-EonTM) and developer of medical devices utilising the key properties of Elast-EonTM, provided the following trading update ahead of the publication of the Group’s audited final results for the financial year ended 31 March 2019 which are expected to be released in mid-July 2019.

Growth in polymer licensing revenue from £404k to over £460k

Strong cash position of £2.4m as at 31 March 2019 (2018: £422k)

Good progress in developing portfolio of medical devices

Confidence in strategy, business model and prospects


Michelmersh Brick (MBH.L) 97p £89.3m

AGM Statement from the specialist brick, land development and landfill company.

Trading in 2019 has been robust with production volumes in line with expectations. Forward sales have also been positive leading the Company to expect a first half weighting to its financial performance for the year as the overall capacity of the five plants within the Group is fixed. Initial performance indicates that the acquisition of Floren in Feb 2019 is proving a sound investment that will contribute to the Group’s trading performance and strategic options moving forward. The Group’s performance to date in 2019 gives the Board confidence in achieving expectations for the full year to 31 Dec 2019.”


Tekcapital (TEK.L) 10.5p £5.71m

The UK intellectual property (IP) investment group focused on creating marketplace value from investing in university technology, announced that portfolio company Lucyd Ltd, the developer of an eShop for innovative eyewear, has launched Loud 2.0, its new line of prescription-ready Bluetooth® music glasses.   

Lucyd’s new collection offers 10 exclusive, fashion-forward designs, coupled with more than 20 different types of proper corrective lenses, all day battery life, and a host of useful features.

Lucyd Loud correct your vision and are Bluetooth-enabled, making it possible to listen to music, make phone calls and use voice assistants from your prescription glasses. The voice assistant function enables a number of useful apps to be used handsfree, such as Uber® and Cashapp®. It’s perfect for cyclists, runners, athletes and people on the go, because you can still hear what’s happening around you, while listening to your tunes and staying connected.


Eagle Eye Solutions (EYE.L) 153p £38.5m

The “marketing technology company, Eagle Eye Solutions, is partnering with News America Marketing (NAM), the premier marketing services company in the U.S. and Canada, to deliver next-generation retailer and brand marketing solutions. The agreement establishes a partnership where the parties will collaborate to provide personalised digital and analogue advertising and incentives in real time to shoppers in the North American region.

‘This agreement with News America Marketing represents an exciting new opportunity to introduce next-generation marketing solutions in North America with a partner that has a great product portfolio and an extensive client base,’ said Tim Mason, CEO of Eagle Eye. ‘Together, Eagle Eye and NAM will be able to offer market-leading promotions programming, capable of delivering data-driven, personalized offers and messages to digitally-connected consumers in real time.”


KR1 (NEX:KR1) 9.5p £13m

“The digital asset investment company, announced that the Company is now generating significant revenue in the form of ‘staking yields’ on the Cosmos Network,  one of the major ‘Proof-of-Stake’ investments in KR1’s portfolio, alongside Polkadot and Dfinity.

Following the launch of the Cosmos Network on the 14 March 2019, staking yield activity is generating significant revenue for KR1 plc on an ongoing basis in the Cosmos Network’s native ATOM digital asset. To date, KR1 has generated 15,463 ATOM. The Company announced that it has realised the accrued revenue from staking yields thus far, realising 15,463 ATOM at an average price of $4.76 per ATOM for a total of $73,671. Cosmos is a ‘Proof-of-Stake’ network that, unlike ‘Proof-of-Work’ networks, such as Bitcoin, does not require enormous computing power and the energy consumption related to this, to guarantee the security and censorship-resistance of the network.”


Ideagen (IDEA.L) 136p £281m

FY Apr 19 trading update from the supplier of Information Management software to highly regulated industries.

The Board reported that trading for the year to 30 April 2019 has been strong and results are expected to be marginally ahead of market expectations representing the Group’s tenth consecutive year of revenue and adjusted EBITDA growth. The Group expects to report revenue up 29% at approximately £46.7m, (FY2018: £36.1m) and adjusted EBITDA up 30% at approximately £14.3 m (FY2018: £11m).

Trading was once again robust across all key verticals with the Group delivering organic revenue growth of c.8% and generating a substantial increase in recurring revenues as the transition to a SaaS model continues. The Annual Recurring Revenue book was up 44% at approximately £36.4m driven by an increase in SaaS bookings coupled with the three acquisitions made within the year.


Hardide (HDD.L) 53p £26.6m

The developer and provider of advanced surface coating technology, announced that its Hardide-A coating has been selected as the replacement for hard chrome plating (HCP) on Airbus A380 compression flap pads. 

Hardide-A has been developed specifically to meet the needs of the aerospace industry; it is a hard wearing, quality product, environmentally compliant with demonstrable long-term performance qualities.

Interim results (Mar19).

Record revenue for a first half-year – up by 9% to £2.35m (H1 2018:

Gross profit of £1.05m (H1 2018:

Group operating loss of £0.66m (H1 2018: £0.32m

EBITDA loss of £0.44m (H1 2018: loss of

Successful fundraising of £3.6m in March 2019 to fund continuing investment and long-term growth

Cash at bank at 31 March 2019 of £5.35m (£3.23m at 31 March


Physiomics* (PYC.L) 3.65p £2.77m

The provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, confirmed that is has successfully completed the Innovate UK grant project announced in March 2018.  The project was formally signed off by Innovate UK following a final project meeting in April 2019. The Company can confirm that, in line with expectations, it received total funding of £68k from Innovate UK over the course of the project. This covers the anticipated costs of the project.

The project “Prostate Cancer Chemotherapy Precision Dosing” addressed the acknowledged challenge of effective under- or over-dosing of individual patients following administration of the same amount of chemotherapy agent, due to the variability of patients’ responses to drugs.

Physiomics is exploring the approval of the tool as a medical device which would likely  require further clinical validation before it could be commercialised, but it is possible the tool could be used earlier in research settings thus creating the possibility of nearer term revenue potential. 


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.